Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
4
×
boston top stories
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
boston
deals
dna
agios therapeutics
azacitidine
base editing
beta-thalassemia
biobucks
biofourmis
biovotion
branden moriarty
broad institute
calistoga pharmaceuticals
car-t immunotherapy
cas13
checkpoint inhibitors
chugai pharmaceutical
clinical trials
crispr therapeutics
crispr-cas9
dacogen
david liu
decitabine
edbi
editas medicine
editor
editr
enzyme
epigenetics
epizyme
farydak
fda
What
startup
4
×
therapeutics
4
×
million
adding
aims
analytics
approach
based
beam
bets
biofourmis
biotech
boost
called
cancer
cas
crispr
data
debuts
developing
devices
digital
drug
drugs
editas
editing
editor
employs
epigenetic
epigenetics
expensive
far
field
flagship’s
founders
gene
gilead
globally
gotten
harvard
Language
unset
Current search:
therapeutics
×
startup
×
" boston blog main "
×
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
To Boost Cancer Pipeline, Gilead Bets at Least $50M on Startup Tango
@xconomy.com
5 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M
